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required a small increase in core temperature to 33.6*0.15”C. Meperidine and buspirone 
did not cause respiratory depression or other complications. Patients with shivering were 
younger (54 * 10 years vs. 59 * 12 years. p=O.O4), and received a higher total bolus 
dose of meperidine than those without shivering (156 f 66mg vs. 120 f 66mg, p=O.Ol). 
Mean patient weight and body surface area were similar in bath groups and no other 
demographic, clinical or hemodynamlc predictors of shivering were identified. 
Conclusion: Our results indicate that combination treatment with surface warming, bus- 
pirone and meperidine is safe and effective in patients with AMI, and provides a novel 
method for counteracting thermoregulatory defenses to systemic hypothermia during 
endovascular cooling. 
SES to control bare stents (CS), 462 pts (44%) had single vessel LAD treatment. In this 
cohort, reference vessel size was 2.74mm and lesion length was 14.0 mm. 
Results: Clinical (@ 9 months) and angiographic (@ 8 months) outcomes were com- 
pared in the SES and CS LAD subgroups (see table). 
Conclusions: The SIRIUS LAD substudy indicates striking improvement after SES in all 
clinical and angiographic efficacy parameters compared with CS. These SES results are 
equivalent to those reported after LIMA surgery, and thus, SES should be considered the 
new standard of care for stngle vessel LAD therapy. 
Follow-up parameter 
TLR (“‘o) 
TVR (%) 
MACE (%) 
Res (%): in-stent 
Res (%). In-lesion 
SES (n=234) CS (n=228) p value 
5.4 21.2 <O.OOl 
7.6 23.0 <O.OOl 
8.8 22.9 <O.OOl 
2.0 41.6 <O.OOl 
10.1 41.6 <O.OOl 
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1198-178 Volumetric Analysis of In-Stem lntimal Hyperplasia in 
Diabetic Patients Treated With or Without Abciximab: 
Results of the DANTE Randomized Trial 
Aurea J. Chaves, Luiz Mattes, Alexandre A. Abizaid, Rodolfo Staico. Fausto Feres, 
Marinella Centernero, LUIZ F. Tanajura, Andrea S. Abizaid, Ana S&as. lbraim Pinto, 
Marco Costa, Arilson Radrigues, Angela Paes, Amanda Sousa, Jose Eduardo M. Sousa, 
lnstituto Dante Pazzanese de Cardiologia. Sao Paula, Brazil 
Background: EPISTENT data showed that diabetic patients treated with stentiabcix- 
imab had their target vessel revascularlzation (TVR) reduced by approximately 50% 
when compared to stenffplacebo. Whether this is a result of a lower angiographic rest- 
enosis rate remains a subject of debate. Objective: To determine if abciximab is associ- 
ated with a reduced in-stent neointimal hyperplasia (IH), measured by intravascular 
ultrasound (IVUS), in diabetic patients. Method: The DANTE trial enrolled 96 diabetic 
patients (96 lesions) who underwent elective MULTILINK stat implantation for a de nova 
lesion of a native coronary artery randomized to be treated with or without abciximab. 
They were scheduled to undergo a 6.month angiographic and IVUS evaluation. Sample 
size calculations showed that 44 stented lesions/arm would be required to show a 25% 
reduction I” IH. Results: 
StenffAbciximab (n=47) Stem (n=49) p 
Age. Y 
Female, % 
Insulin Treated, % 
56.9 f 9.8 
46.8 
19.1 
Lesion Length, mm 11.5 * 4.7 
Stented Segment, mm 18.1 e4.0 
Reference Diameter, mm 2.99 * 0.49 
MLD pre 0.95 * 0.46 
MLD post 2.77 * 0.39 
MLD fup 1.75 * 0.69 
Acute Gain, mm 1.81 * 0.42 
Late LOSS, mm 1.03 * 0.63 
250% Restenosis, % 17.8 
30.day MACE, % 0 
60.6 f 8.5 
55.1 
16.3 
11.0 * 3.5 
19.8 f 5.6 
2.89 * 0.47 
0.84 * 0.35 
2.72 f 0.42 
1.66 f 0.63 
1.88 * 0.47 
1.07 * 0.58 
22.9 
0 
0.375 
0.416 
0.717 
0.537 
0.106 
0.283 
0.187 
0.574 
0.388 
0.484 
0.736 
0.539 
6month MACE, % 10.6 
NR, % 8.5 
Neointimal Volume, mm3 53.6 * 28.5 
Volume Obstruction, % 41.3 * 21.0 
MACE: death, Ml @-3x CKMB) or TVR 
22.4 0.121 
16.3 0.274 
60.7 + 40.8 0.344 
40.5 * 18.3 0.853 
Conclusion: In our study, volumetric analysis obtained in the d-month IVUS evaluation, 
showed that the administration of abciximab at the time of coronary stent implantation, 
was not associated with a reduction of neointimal hyperplasia in diabetic patients. 
1198-l 79 Should Sirolimus-Eluting Stents Be the New Standard 
for Left Anterior Descending Therapy? A SIRIUS 
Substudy 
Jeffrev W. Moses Dean Kereiakes, David 0. Williams, John Douglas, Charles Lambert. 
Charles Simonton, Michael Cleman, Charles Davidson, Timothy Vellinga, Martin B. 
Leon, Cardiovascular Research Foundation, New York, NY 
Background: The universal adoption of stenting to treat single vessel LAD disease has 
been llmited by increased target vessel revascularization -20.30%. leading to the pro- 
posal of LIMA surgery as an alternative therapy. Importantly, the effects of sirolimus-elut- 
Ing stents (SES) on LAD restenosis (Res) is not well defined. 
Methods: Of the 1058 pts in the randomized double-blind SIRIUS trial, which compared 
TLR=target lesion revascularizatlon 
TVR=target vessel revascularization 
MACE = major adverse cardiac events (death, MI, and repeat revascularlzation) 
1198-180 Effects of Sirolimus-Eluting Stents in Diabetic Patients: 
Volumetric Intravascular Ultrasound Analysis From the 
SIRIUS Trial 
Junva Ako, Yoshihiro Morino, Yasuhiro Honda, Shinjo Sonoda, Mitsuyasu Terashima, Ali 
Hassan, Judith J. Jaeger, Charles A. Simonton, David K. Roberts, Michael W. Cleman, 
Martin B. Leon, Jeffrey W. Moses, Paul G. Yock, Peter J. Fitzgerald. the SIRIUS 
investigators, Stanford University, Stanford, CA, Lenox Hill Hospital, New York NY 
Background: Exaggerated intimal hyperplasia has been reported to contribute to 
increased restenosis after percutaneous coronary tnterventlons in diabetic patients. The 
effects of drug-eluting stents in diabetic patients have not been well investigated. 
Methods: IVUS data were obtained from SIRIUS, a prospective, randomized, multi- 
center trial comparing sirolimus-eluting Bx VELOCITY stents (SES) vs. bare metal Bx 
VELOCITY stems (BMS). Eight-month follow-up 3-D IVUS analysis was available in 95 
cases (BMS 44: SES 51). Mean lumen (LA), stent @A), and neointimal areas (NIA) were 
obtained by dividing each volume with stent length. Cross sectional narrowing (CSN) 
was calculated as NIA divided by SA. The variables were compared by stent types (SESI 
EMS), presence of diabetes, and their Interactions. 
Results: There were 25 diabetic patients (BMS 13: SES 12). BMS showed a trend of 
decreased LA in diabetic patients compared to non-diabetic patients (p=O.O8). SES sig- 
nificantly suppressed neointimal hyperplasia in both diabetic and non-diabetic patients. 
There was no significant interaction effect between stent types and diabetes, indicating 
that the extent of neointimal suppression by SES was not affected by the presence of 
diabetes. 
Conclusions: Volumetric IVUS results of the SIRIUS trial suggest that sirolimus-eluting 
stents can provide suppression of neointimal hyperplasia that is as substantital in dia- 
betic patients as in non-diabetic patients. 
Table (*p=O.O8 vs. DM(-). BMS) 
BMS (n=44) SES (n=51) p-value 
NIA (mm3lmm) DM(-) 2.5il.3 0.18iO.3 <0.0001 
DM(+) 2.4kl.2 0.01*0.13 
LA (mm3lmm) DM(-) 5.3kl.7 6.7e2.0 <0.001 
DM(+) 4.3il.7’ 6.221.8 
%CSN DM(-) 31.4k12.8 2.8+5.1 <0.0001 
DM(+) 36.1i16.8 1.7i2.1 
Minimum lumen area (mm2) DM(-) 3.2kl.3 5.ikl.8 <0.0001 
DM(+) 3.1+2.0 4.5*1.7 
1198-181 About the Use of the ACHIEVE Paclitaxel Eluting 
Stent in Treatment of Restenotic Lesions: A 
Subanalysis of the 30-Day Safety Data of DELIVER II 
Antonio L. Bartorelli, Eberhard Grube, Didier Blanchad. Anthony Genhlick. Carlos 
Macava. Sophie Henrv. ChrIstran Homsv. on behalf of the DELIVER II investiaators. 
Centro Cardiologico Monzino, Milano, Italy, GUIDANT Europe, Diegem, Belgium 
Background: Many interventional cardiologists believe that restenosls following angio- 
plasty or stating is the most significant and pressing problem in the field of cardiology 
today. Stenting of coronary arteries resulted in a reduction of restenosis to 15.30% fol- 
lowing treatment of de nova lessons. But when restenosis of a stent does occur, recur- 
rence of in-stent restenosis treated with repeat PTCA ranges from 30% to as high as 
80% for diffuse in-stent restenosis. The DELIVER II study is a 1500 patients prospective, 
non-randomized, multi-center evaluation of the ACHIEVETM paclitaxel eluting Coronary 
Stat System in the treatment of lesions with high risk of revascularization due to rest- 
enosis. Such lesions include Chronic Total and Sub-Total Occlusions &TO). lesions 
